HIV-Selectest Enzyme Immunoassay and Rapid Test: Ability To Detect Seroconversion following HIV-1 Infection-Reference-Cited by-同舟云学术

HIV-Selectest Enzyme Immunoassay and Rapid Test: Ability To Detect Seroconversion following HIV-1 Infection

Published:2010-01 Issue:1 Volume:48 Page:281-285
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Khurana Surender¹,Norris Philip J.²³,Busch Michael P.²³,Haynes Barton F.⁴,Park Susan¹,Sasono Pretty¹,Mlisana Koleka⁵,Salim Abdool Karim⁵,Hecht Frederick M.³,Mulenga Joseph⁶⁷,Chomba Elwyn⁷,Hunter Eric⁸,Allen Susan⁹,Nemo George¹⁰,Rodriguez-Chavez Isaac R.¹¹,Margolick Joseph B.,Golding Hana¹

Affiliation:

1. Division of Viral Products, CBER, FDA, Bethesda, Maryland 20892

2. Blood Systems Research Institute

3. University of California at San Francisco, San Francisco, California 94118

4. Duke Human Vaccine Institute, Durham, North Carolina 27710

5. Center for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa 4013

6. Zambia-Emory HIV Research Project (ZEHRP)

7. Zambia Blood Transfusion Service, Lusaka, Zambia

8. Emory Vaccine Research Center, Atlanta, Georgia 30329

9. Emory University School of Public Health, Atlanta, Georgia 30322

10. Transfusion Medicine, National Heart Lung and Blood Institute, NIH, Bethesda, Maryland 20817

11. AIDS and Immunosuppression Program, National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland 20892-4878

Abstract

ABSTRACT HIV-Selectest is a serodiagnostic enzyme immunoassay (EIA), containing p6 and gp41 peptides, designed to differentiate between vaccine-induced antibodies and true infections. A rapid test version of the HIV-Selectest was developed. Both assays detected HIV antibodies in men and women within 2 to 4 weeks of infection, with sensitivity similar to third-generation EIAs.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01573-09

Reference11 articles.

1. Dynamics of HIV viremia and antibody seroconversion in plasma donors

2. Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection

3. Inflammatory Genital Infections Mitigate a Severe Genetic Bottleneck in Heterosexual Transmission of Subtype A and C HIV-1

4. Human Immunodeficiency Virus (HIV) Vaccine Trials: a Novel Assay for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies

5. Khurana, S., J. Needham, S. Park, B. Mathieson, M. P. Busch, G. Nemo, P. Nyambi, S. Zolla-Pazner, S. Laal, J. Mulenga, E. Chomba, E. Hunter, S. Allen, J. McIntyre, I. Hewlett, S. Lee, S. Tang, E. Cowan, C. Beyrer, M. Altfeld, X. G. Yu, A. Tounkara, O. Koita, A. Kamali, N. Nguyen, B. S. Graham, D. Todd, P. Mugenyi, O. Anzala, E. Sanders, N. Ketter, P. Fast, and H. Golding. 2006. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. J. Acquir. Immune Defic. Syndr.43:304-312.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards Novel HIV-1 Serodiagnostic Tests without Vaccine-Induced Seroreactivity;Microbiology Spectrum;2023-06-15

2. Detection of porcine cytomegalovirus, a roseolovirus, in pig ovaries and follicular fluid: implications for somatic cells nuclear transfer, cloning and xenotransplantation;Virology Journal;2023-01-27

3. Ebola-Detect: A differential serodiagnostic assay for Ebola virus infections and surveillance in the presence of vaccine-induced antibodies;eBioMedicine;2022-08

4. The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update;Journal of Women's Health;2016-03

5. HIV vaccine-induced sero-reactivity: A challenge for trial participants, researchers, and physicians;Vaccine;2015-03